Proteolytic stress: A unifying concept for the etiopathogenesis of Parkinson's disease

Annals of Neurology

Volumn 53, Issue SUPPL. 3, 2003, Pages

  McNaught, Kevin St P ^a   Olanow, C Warren ^a   Schapira, ^b   Jenner, ^b   Isacson, ^b   Hunot, ^b   Tatton, ^b   Beal, ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; OXYGENASE; PARKIN; PROTEOME; UBIQUITIN;

AGING; CYTOTOXICITY; ETIOLOGY; HEREDITY; HUMAN; LEWY BODY; MUTATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SUBSTANTIA NIGRA;

ALPHA-SYNUCLEIN; CYSTEINE ENDOPEPTIDASES; HUMANS; LEWY BODIES; LIGASES; MULTIENZYME COMPLEXES; NERVE DEGENERATION; NERVE TISSUE PROTEINS; PARKINSON DISEASE; PEPTIDE HYDROLASES; POINT MUTATION; PROTEASOME ENDOPEPTIDASE COMPLEX; SUBSTANTIA NIGRA; SYNUCLEINS; THIOLESTER HYDROLASES; UBIQUITIN THIOLESTERASE; UBIQUITIN-PROTEIN LIGASES;

EID: 0037378898     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10512     Document Type: Review

References (92)

1. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996;55:259-272.
2. Pollanen MS, Dickson DW, Bergeron C. Pathology and biology of the Lewy body. J Neuropathol Exp Neurol 1993;52:183-191.
3. Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 1999;22:123-144.
4. Jenner P, Olanow CW. Understanding cell death in Parkinson's disease. Ann Neurol 1998;44:S72-S84.
5. McNaught KS, Olanow CW, Halliwell B, et al. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev Neurosci 2001;2:589-594.
6. Gasser T. Genetics of Parkinson's disease. J Neurol 2001;248:833-840.
7. McNaught KS, Jenner P. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci Lett 2001;297:191-194.
8. McNaught KS, Belezaire R, Isacson O, et al. Altered proteasomal function in Parkinson's disease. Exp Neurol 2003;179:38-46.
9. Pickart CM. Mechanisms underlying ubiquitination. Annu Rev Biochem 2001;70:503-533.
10. Voges D, Zwickl P, Baumeister W. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem 1999;68:1015-1068.
11. Sherman MY, Goldberg AL. Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 2001;29:15-32.
12. Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001;292:1552-1555.
13. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047.
14. Kruger R, Kuhn W, Muller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998;18:106-108.
15. Spira PJ, Sharpe DM, Halliday G, et al. Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. Ann Neurol 2001;49:313-319.
16. Golbe LI, Di Iorio G, Bonavita V, et al. A large kindred with autosomal dominant Parkinson's disease. Ann Neurol 1990;27:276-282.
17. Duda JE, Giasson BI, Mabon ME, et al. Concurrence of alphasynuclein and tau brain pathology in the Contursi kindred. Acta Neuropathol 2002;104:7-11.
18. Solano SM, Miller DW, Augood SJ, et al. Expression of alphasynuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: genes associated with familial Parkinson's disease. Ann Neurol 2000;47:201-210.
19. Clayton DF, George JM. Synucleins in synaptic plasticity and neurodegenerative disorders. J Neurosci Res 1999;58:120-129.
20. Abeliovich A, Schmitz Y, Farinas I, et al. Mice lacking alphasynuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000;25:239-252.
21. Perez RG, Waymire JC, Lin E, et al. A role for alpha-synuclein in the regulation of dopamine biosynthesis. J Neurosci 2002; 22:3090-3099.
22. Xu J, Kao SY, Lee FJ, et al. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med 2002;8:600-606.
23. Conway KA, Rochet JC, Bieganski RM, Lansbury PT Jr. Kinetic stabilization of the alpha-synuclein protofibril by a dopaminealpha-synuclein adduct. Science 2001;294:1346-1349.
24. Souza JM, Giasson BI, Lee VM, Ischiropoulos H. Chaperonelike activity of synucleins. FEBS Lett 2000;474:116-119.
25. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2001;2:492-501.
26. McLean PJ, Kawamata H, Hyman BT. Alpha-synuclein-enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons. Neuroscience 2001;104:901-912.
27. Tofaris GK, Layfield R, Spillantini MG. alpha-Synuclein metabolism and aggregation is linked to ubiqutin-independent degradation by the proteasome. FEBS Lett 2001;509:22-26.
28. Pendleton RG, Parvez F, Sayed M, Hillman R. Effects of pharmacological agents upon a transgenic model of Parkinson's disease in Drosophila melanogaster. J Pharmacol Exp Ther 2002; 300:91-96.
29. Feany MB, Bender WW. A Drosophila model of Parkinson's disease. Nature 2000;404:394-398.
30. Auluck PK, Chan E, Trojanowski JQ, et al. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model of Parkinson's disease. Science 2002;295:865-868.
31. Kirik D, Rosenblad C, Burger C, et al. Parkinson-like neurodegeneration induced by targeted overexpression of alphasynuclein in the nigrostriatal system. J Neurosci 2002;22:2780-2791.
32. Giasson BI, Duda JE, Quinn SM, et al. Neuronal alphasynucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 2002;34:521-533.
33. Masliah E, Rockenstein E, Veinbergs I, et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 2000;287:1265-1269.
34. Klein RL, King MA, Hamby ME, Meyer EM. Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra. Hum Gene Ther 2002;13:605-612.
35. Matsuoka Y, Vila M, Lincoln S, et al. Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol Dis 2001;8:535-539.
36. Bennett MC, Bishop JF, Leng Y, et al. Degradation of alphasynuclein by proteasome. J Biol Chem 1999;274:33855-33858.
37. Tanaka Y, Engelender S, Igarashi S, et al. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum Mol Genet 2001;10:919-926.
38. Stefanis L, Larsen KE, Rideout HJ, et al. Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci 2001;21:9549-9560.
39. Lee M, Hyun D, Halliwell B, Jenner P. Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. J Neurochem 2001;76:998-1009.
40. Ghee M, Fournier A, Mallet J. Rat alpha-synuclein interacts with Tat binding protein 1, a component of the 26S proteasomal complex. J Neurochem 2000;75:2221-2224.
41. Mizuno Y, Hattori N, Mori H, et al. Parkin and Parkinson's disease. Curr Opin Neurol 2001;14:477-482.
42. Bonifati V, De Michele G, Lucking CB, et al. The parkin gene and its phenotype. Italian PD Genetics Study Group, French PD Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. Neurol Sci 2001; 22:51-52.
43. Mori H, Kondo T, Yokochi M, et al. Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology 1998;51:890-892.
44. Farrer M, Chan P, Chen R, et al. Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol 2001;50:293-300.
45. Shimura H, Hattori N, Kubo S, et al. Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients. Ann Neurol 1999;45:668-672.
46. Shimura H, Hattori N, Kubo S, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 2000;25:302-305.
47. Shimura H, Schlossmacher MG, Hattori N, et al. Ubiquitination of a new form of {alpha}-synuclein by parkin from human brain: implications for Parkinson's disease. Science 2001;293:263-269.
48. Imai Y, Soda M, Inoue H, et al. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of parkin. Cell 2001;105:891-902.
49. Chung KK, Zhang Y, Lim KL, et al. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat Med 2001; 7:1144-1150.
50. Zhang Y, Gao J, Chung KK, et al. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc Natl Acad Sci USA 2000;97:13354-13359.
51. Hyun DH, Lee M, Hattori N, et al. Effect of wild-type or mutant parkin on oxidative damage, nitric oxide, antioxidant defences and the proteasome. J Biol Chem 2002;277:28572-28577.
52. Leroy E, Boyer R, Auburger G, et al. The ubiquitin pathway in Parkinson's disease. Nature 1998;395:451-452.
53. Wintermeyer P, Kruger R, Kuhn W, et al. Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients. Neuroreport 2000;11:2079-2082.
54. Zhang J, Hattori N, Leroy E, et al. Association between a polymorphism of ubiquitin carboxy-terminal hydrolase L1 (UCHL1) gene and sporadic Parkinson's disease. Parkinsonism Relat Disord 2000;6:195-197.
55. Wilkinson KD, Deshpande S, Larsen CN. Comparisons of neuronal (PGP 9.5) and non-neuronal ubiquitin C-terminal hydrolases. Biochem Soc Trans 1992;20:631-637.
56. Saigoh K, Wang YL, Suh JG, et al. Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat Genet 1999;23:47-51.
57. McNaught KSP, Mytilineou C, JnoBaptiste R, et al. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J Neurochem 2002;80:1-6.
58. Alam ZI, Daniel SE, Lees AJ, et al. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J Neurochem 1997;69:1326-1329.
59. Lopiano L, Fasano M, Giraudo S, et al. Nuclear magnetic relaxation dispersion profiles of substantia nigra pars compacta in Parkinson's disease patients are consistent with protein aggregation. Neurochem Int 2000;37:331-336.
60. Spillantini MG, Crowther RA, Jakes R, et al. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 1998;95:6469-6473.
61. Wakabayashi K, Engelender S, Yoshimoto M, et al. Synphilin-1 is present in Lewy bodies in Parkinson's disease. Ann Neurol 2000;47:521-523.
62. Giasson BI, Duda JE, Murray IV, et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000;290:985-989.
63. Good PF, Hsu A, Werner P, et al. Protein nitration in Parkinson's disease. J Neuropathol Exp Neurol 1998;57:338-342.
64. Lowe J, McDermott H, Landon M, et al. Ubiquitin carboxylterminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases. J Pathol 1990;161:153-160.
65. Ii K, Ito H, Tanaka K, Hirano A. Immunocytochemical colocalization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly. J Neuropathol Exp Neurol 1997;56:125-131.
66. Shashidharan P, Good PF, Hsu A, et al. TorsinA accumulation in Lewy bodies in sporadic Parkinson's disease. Brain Res 2000; 877:379-381.
67. Grune T, Reinheckel T, Davies KJ. Degradation of oxidized proteins in K562 human hematopoietic cells by proteasome. J Biol Chem 1996;271:15504-15509.
68. Bulteau AL, Lundberg KC, Humphries KM, et al. Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion. J Biol Chem 2001;276:30057-30063.
69. Johnston JA, Ward CL, Kopito RR. Aggresomes: a cellular response to misfolded proteins. J Cell Biol 1998;143:1883-1898.
70. Wigley WC, Fabunmi RP, Lee MG, et al. Dynamic association of proteasomal machinery with the centrosome. J Cell Biol 1999;145:481-490.
71. Kopito RR. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol 2000;10:524-530.
72. Davies KJ. Degradation of oxidized proteins by the 20S proteasome. Biochimie 2001;83:301-310.
73. McNaught KStP, Shashidharan P, Perl DP, et al. Aggresome-related biogenesis of Lewy bodies. Eur J Neurosci 2000;16:2136-2148.
74. Rideout HJ, Larsen KE, Sulzer D, Stefanis L. Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells. J Neurochem 2001; 78:899-908.
75. McNaught KSP, Jenner P, Olanow CW. proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport 2002;13:1437-1441.
76. Nam S, Smith DM, Dou QP. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem 2001;276:13322-13330.
77. Yoritaka A, Hattori N, Uchida K, et al. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci USA 1996;93:2696-2701.
78. Schapira AH, Mann VM, Cooper JM, et al. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem 1990;55:2142-2145.
79. Betarbet R, Sherer TB, MacKenzie G, et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000;3:1301-1306.
80. Lee HJ, Shin SY, Choi C, et al. Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. J Biol Chem 2001;27:27.
81. Floor E, Wetzel MG. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J Neurochem 1998;70:268-275.
82. Hirsch EC, Faucheux B, Damier P, et al. Neuronal vulnerability in Parkinson's disease. J Neural Transm Suppl 1997;50:79-88.
83. Paxinou E, Chen Q, Weisse M, et al. Induction of alphasynuclein aggregation by intracellular nitrative insult. J Neurosci 2001;21:8053-8061.
84. El-Khodor BF, Kholodilov NG, Yarygina O, Burke RE. The expression of mRNAs for the proteasome complex is developmentally regulated in the rat mesencephalon. Brain Res Dev Brain Res 2001;129:47-56.
85. Gaczynska M, Osmulski PA, Ward WF. Caretaker or undertaker? The role of the proteasome in aging. Mech Ageing Dev 2001;122:235-254.
86. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
87. Hoffner G, Kahlem P, Djian P. Perinuclear localization of huntingtin as a consequence of its binding to microtubules through an interaction with beta-tubulin: relevance to Huntington's disease. J Cell Sci 2002;115:941-948.
88. Waelter S, Boeddrich A, Lurz R, et al. Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Mol Biol Cell 2001; 12:1393-1407.
89. French BA, van Leeuwen F, Riley NE, et al. Aggresome formation in liver cells in response to different toxic mechanisms: role of the ubiquitin-proteasome pathway and the frameshift mutant of ubiquitin. Exp Mol Pathol 2001;71:241-246.
90. Serrando M, Casanovas A, Esquerda JE. Occurrence of glutamate receptor subunit 1-containing aggresome-like structures during normal development of rat spinal cord interneurons. J Comp Neurol 2002;442:23-34.
91. Ma J, Lindquist S. Wild-type PrP and a mutant associated with prion disease are subject to retrograde transport and proteasome degradation. Proc Natl Acad Sci USA 2001;98:14955-14960.
92. Cummings CJ, Reinstein E, Sun Y, et al. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Neuron 1999;24:879-892.